



THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant : Charles D. Y. Sia Confirmation No.: 4350
Appl'n No. : 09/055,744
Filed : April 7, 1998
Title : HIV-SPECIFIC CYTOTOXIC T-CELL RESPONSES
Grp./A.U. : 1648
Examiner : Emily M. Le
Docket No. : 1038-746 MIS/jb
Customer No.: 24223
Date : October 27, 2004

BY COURIER

Mail Stop Amendment
Commissioner of Patents
P.O. Box 1450
Alexandria, Virginia 22313-1450
U.S.A.

AMENDMENT

Sir:

In response to the Office Action of May 27, 2004, please amend the
above-identified application as follows:

Amendments to the Specification begin on page 2 of this paper.

Amendments to the Claims are reflected in the listing of claims which
begins on page 3 of this paper.

Remarks/Arguments begin on page 5 of this paper.

11/03/2004 MBLAND 00000005 09055744

01 FC:1253

980.00 QP

REMARKS/ARGUMENTS

Petition is hereby made under the provisions of 37 CFR 1.136(a) for an extension of three months of the period for response to the Office Action. Our cheque in respect of the prescribed fee is enclosed.

The Examiner considered that the Voluntary Amendment, presumably that submitted June 11, 1999, failed to place the application into sequence compliance.

In particular, the Examiner indicated that the Sequence pages contain new matter, in that the contents disclosed therein do not match those presented in the original specification. The Examiner indicated that SEQ ID No:9 as contained in the Sequence Listing contains 65 amino acids whereas the sequence identified in Table 2, page 17 as being SEQ ID No:9, contains 67 amino acids.

Submitted herewith is a substitute Sequence Listing in hard copy and computer-readable forms. It is hereby stated that the Sequence Listing in hard copy and computer-readable forms are the same and involve no new matter. This Amendment includes direction to substitute the hard copy of the Sequence Listing for the existing one.

Upon examination of the Sequence Listing, it was found that two amino acids had been inadvertently omitted between amino acids 47 and 48 in the Sequence Listing. This matter has been corrected on the enclosed substitute Sequence Listing.

It is submitted that the application is now sequence compliant.

The Examiner required submission of new corrected drawings because the current drawings contain text which is not clearly written, pointing to Figure 2.

This rejection is a provisional one, since the conflicting claims have not yet been patented. The matter may, therefore, be deferred to a later time.

It is believed that this application is now in condition for allowance and early and favourable consideration and allowance are respectfully solicited.

Respectfully submitted,



Michael I. Stewart
Reg. No. 24,973

Toronto, Ontario, Canada,
(416) 595-1155
FAX No. (416) 595-1163